AK4 inhibitors belong to a specific category of chemical compounds designed to target and inhibit the activity of the AK4 protein, also known as Adenylate Kinase 4. Adenylate kinases are enzymes that play a central role in cellular energy metabolism by facilitating the interconversion of adenine nucleotides, such as ATP (adenosine triphosphate) and ADP (adenosine diphosphate). AK4, in particular, is primarily localized in the mitochondria, the energy-producing organelles within cells, where it participates in the regulation of cellular energy balance. It is involved in the phosphorylation of AMP (adenosine monophosphate) to generate ADP, contributing to the maintenance of ATP/ADP ratios in the mitochondria. Inhibitors of AK4 are primarily developed for research purposes, serving as valuable tools for scientists and researchers to investigate the molecular mechanisms and functions associated with this enzyme in the context of cellular energy metabolism.
Typically, AK4 inhibitors are composed of small molecules or chemical compounds specifically designed to interact with the AK4 protein, disrupting its normal enzymatic activity. By inhibiting AK4, these compounds can potentially impact the balance of adenine nucleotides within the mitochondria, influencing cellular energy metabolism and related processes. Researchers use AK4 inhibitors in laboratory settings to manipulate the activity of this enzyme and study its roles in cellular energy homeostasis, mitochondrial function, and overall cellular physiology. These inhibitors provide valuable insights into the molecular mechanisms by which AK4 contributes to cellular energy metabolism and contribute to a deeper understanding of its significance in cellular biology. While AK4 inhibitors may have broader implications, their primary purpose is to assist scientists in deciphering the intricacies of AK4-mediated energy regulation.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $73.00 $238.00 $717.00 $2522.00 $21420.00 | 53 | |
Actinomycin D intercalates into DNA, potentially preventing RNA polymerase from transcribing the AK4 gene. | ||||||
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $88.00 $200.00 | 13 | |
Triptolide may impair the transcription of various genes, possibly including AK4 by an undefined mechanism. | ||||||
DRB | 53-85-0 | sc-200581 sc-200581A sc-200581B sc-200581C | 10 mg 50 mg 100 mg 250 mg | $42.00 $185.00 $310.00 $650.00 | 6 | |
DRB inhibits RNA polymerase II, potentially reducing transcription of the AK4 gene. | ||||||
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | $260.00 $1029.00 | 26 | |
α-Amanitin selectively inhibits RNA polymerase II, which could reduce AK4 mRNA synthesis. | ||||||
Cordycepin | 73-03-0 | sc-203902 | 10 mg | $99.00 | 5 | |
Cordycepin is an adenosine analog that may prematurely terminate mRNA elongation, potentially affecting AK4 mRNA levels. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $57.00 $182.00 $92.00 | 21 | |
Camptothecin inhibits DNA topoisomerase I, essential for DNA transcription, possibly reducing AK4 expression. | ||||||
Mitomycin C | 50-07-7 | sc-3514A sc-3514 sc-3514B | 2 mg 5 mg 10 mg | $65.00 $99.00 $140.00 | 85 | |
Mitomycin C cross-links DNA, which may inhibit transcription and thus reduce AK4 expression. | ||||||
Mithramycin A | 18378-89-7 | sc-200909 | 1 mg | $54.00 | 6 | |
Mithramycin A binds to DNA and may inhibit transcription factor binding, potentially affecting AK4 expression. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $68.00 | 2 | |
Chloroquine intercalates into DNA, which may affect DNA replication and transcription, potentially altering AK4 expression. | ||||||
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $32.00 $170.00 $385.00 | 63 | |
Etoposide inhibits DNA topoisomerase II, which could lead to a decrease in transcription levels affecting AK4 expression. |